

## **PSMA PET highlights need for updated prostate cancer therapy guidelines**

June 14 2022



Heat maps of PSMA PET prostatic fossa recurrence in patients with recurrence limited to the prostate fossa (miTr N0 M0, n=127), pelvic nodal disease (miTr N1 M0, n=30), distant organs/extra-pelvic nodal disease (miTr N0 M1, n=32) and pelvic nodal plus distant organs/extra-pelvic nodal disease (miTr N1 M1, n=37). The yellow contour represents the RTOG CTV. Credit: Ida Sonni et al, Abstract 486, SNMMI 2022 Annual Meeting, https://www.xcdsystem.com/snm mi/program/2ATIJc8/index.cfm?pgid=237&qfixed=1&sessiontype=Oncology:% 20Clinical%20Therapy



Current guidelines used to plan salvage radiation treatments in patients with local recurrence of prostate cancer should be updated to take into consideration information derived from novel imaging modalities, such as PSMA PET, according to research presented at the Society of Nuclear Medicine and Molecular Imaging 2022 Annual Meeting. The study showed that PSMA PET was effective in identifying recurrences that fell partially or fully outside the clinical target volume as determined by current guidelines. This suggests that PSMA PET can be an invaluable tool for therapy planning.

After a biochemical recurrence of prostate cancer, salvage radiation therapy can be a curative approach. This therapy conducted following contouring guidelines based on expert consensus, such as the Radiation Therapy Oncology Group (RTOG) guidelines. In today's era of <u>precision</u> <u>medicine</u>, study authors sought to determine if PSMA PET imaging could provide more detailed data on patterns of recurrence to inform therapy planning.

Prostate cancer patients who experienced biochemical recurrence after radical prostatectomy were included in the analysis if their PSMA PET/CT imaging showed recurrence in the prostate bed. To analyze the patterns of recurrence, two nuclear medicine physicians documented the areas of recurrence on the PSMA PET/CT, and four radiation oncologists (masked to the PSMA PET/CT findings) delineated the clinical target volume using RTOG guidelines on the CT images of the PET/CT. PSMA recurrence locations were then compared to the RTOG-based clinical target volumes.

PSMA recurrences were fully covered by the clinical target volumes in 54 percent of the patients. In 34 percent of the patients, PSMA recurrence was only partly covered, and in 13 percent of patients the PSMA recurrence was located fully outside of the clinical target volume.



"This study has the potential to redefine prostate bed contouring guidelines to improve the therapeutic ratio for patients receiving postoperative radiotherapy," said Ida Sonni, MD, project scientist in the Department of Radiology at the University of California, Los Angeles. "Nuclear medicine and <u>molecular imaging</u> advances, such as PSMA PET, have the ability to guide individualized, tailored treatments that will ultimately benefit all our patients."

**More information:** Ida Sonni et al, <u>PSMA PET mapping of</u> <u>postoperative local recurrence and impact on prostate fossa contouring</u> <u>guidelines for salvage radiation therapy, Abstract 486</u>, SNMMI 2022 Annual Meeting.

## Provided by Society of Nuclear Medicine and Molecular Imaging

Citation: PSMA PET highlights need for updated prostate cancer therapy guidelines (2022, June 14) retrieved 26 April 2024 from <u>https://medicalxpress.com/news/2022-06-psma-pet-highlights-prostate-cancer.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.